Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure

By sjmartinez • April 8, 2025

Anderson E, Choi Y, Buchsbaum RJ, Klein A, Ky B, Landsburg D, Durani U, Ruddy KJ, Yu AF, Leong D, Asnani A, Neilan TG, Ganatra S, Bloom M, Barac A, Yang EH, Deswal A, Cheng RK, Weiss M, Evens AM, Kahl B, Friedberg JW, Parsons SK, Upshaw JN. Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. Leuk Lymphoma. 2025 Apr 8:1-10. doi: 10.1080/10428194.2025.2484367. Epub ahead of print. PMID: 40195874.

Tags: anthracycline, Cancer, Cancer survivorship, Cardiology/Epi, cardiomyopathy, cardioprotection, heart failure, Publications

Myeloid cell-specific Beta2-adrenergic receptor deletion improves early cardiac injury resolution via de-repression of Anxa1

Nayak TK, Bajpai A, Patwa V, Carter RL, Enjamuri N, Gao E, Rajan S, Xiang YK, Tilley DG. Myeloid cell-specific β2-adrenergic receptor deletion improves early[...]

Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

Oshima A, Serruys PW, Garg S, McEvoy JW, Wood DA, Doenst T, Taggart DP, Puskas JD, Shajahan A, Sharif F, Miyashita K, Tobe A, Tsai[...]

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

Nikitas J, Smith CP, Armstrong WR, Murthy V, Grogan T, Clark K, Moore J, Roberts M, Farolfi A, Reiter RE, Rettig MB, Shen J, Valle[...]